-
-
Civica signs up Profil to run trials for affordable insulin biosimilars
-
After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor
Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy
Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise
Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom
In The News
- Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
- UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
- Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team
Biotechnology Today
more-
Civica signs up Profil to run trials for affordable insulin biosimilars
Civica Rx has chosen Germany-based CRO Profil to run clinical trials for its “affordable insulin”…
After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor
Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy
Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect
Markets
more-
Weekly Market Review – June 25, 2022
Stock Markets Over the holiday-shortened trading week (markets were closed on Monday in observance of…
Bio Space
moreQiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom
Qiming Venture Partners appears to be living up to its…
Why the war in Ukraine might make root canals more difficult
Russia’s assault on Ukraine is being felt worldwide, and the…
ADA: Abbott plans new wearable sensor for catching diabetic ketoacidosis
Fresh off the FDA’s clearance for its latest continuous glucose…
Global News
moreSpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Weekly Market Review – June 25, 2022
Civica signs up Profil to run trials for affordable insulin biosimilars
After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor
Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy
Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise
Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom
Why the war in Ukraine might make root canals more difficult
ADA: Abbott plans new wearable sensor for catching diabetic ketoacidosis
BD launches advanced flow cytometry system that sorts cells based on their inner workings
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect